X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

Content Team by Content Team
18th May 2022
in Drug Development, Manufacturing, News
Conver to wp

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

AbbVie, located in Chicago, and Cugene, based in Waltham, Massachusetts, have formed a partnership to research medicines for autoimmune diseases and cancer. The arrangement focuses on a worldwide licence option for CUG252, a possible best-in-class Treg-selective IL-2 mutein, as well as additional new IL-2 muteins.

Cugene’s CUG252 is an IL-2 mutein that selectively activates and increases immunosuppressive Treg (T regulatory) cells while reducing unwanted IL-2 activity in other cells that express IL-2 receptors. It would be for the treatment of autoimmune illnesses. The medication is currently being tested on healthy volunteers in a Phase I trial. They are using design and engineering techniques to make CUG252 by adjusting interaction with the major IL-2 receptors, Cugene’s chief executive officer, Dr. Luke Li, M.D., confirmed. They are also developing precision engineering tools to develop immune treatments with compelling target biology, such as the cancer-targeted cytokine-based TILKine and VitoKine multiproduct platforms.

AbbVie will pay Cugene $48.5 million upfront as part of the agreement. Cugene will also be entitled to different milestones, a licencing option payment, and graded royalties if AbbVie chooses the option. Cugene will conduct a Phase Ib trial in autoimmune and inflammatory illness patients. If AbbVie chooses to exercise the option, it will be liable for all future clinical research, production, and commercialization. Cugene estimates the asset has the ability to address a wide range of autoimmune and inflammatory conditions, according to Li.

It is crucial to underline that the engagement with AbbVie is centred on autoimmune and inflammatory disorders, he continued. Cugene is also working on creating cancer medications. The team is using molecular simulation to develop compounds that can revive tumor-infiltrated fatigued T cells with great selectivity and efficacy at specific tumour locations. These new compounds are intended for tumour destruction that is both effective and long-lasting.

In a statement, Li expanded on his thoughts about the cooperation. He remarked that they are delighted to join with AbbVie, a global pioneer in the discovery and commercialization of breakthrough immunology medicines. With their commitment to R&D, significant therapeutic area expertise, and global resources, AbbVie is a great partner for CUG252’s therapeutic value for patients who suffer from autoimmune disorders.

Previous Post

Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

Next Post

Proteros and AstraZeneca Boost Collaboration Agreement

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Proteros and AstraZeneca Boost Collaboration Agreement

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In